PUR1500 is an experimental therapy in the discovery stage by Pulmatrix for the treatment of idiopathic pulmonary fibrosis (IPF). The therapy would be a kinase inhibitor with established anti-angiogenesis activity. The company aims to deliver PUR1500 in small, dense, and easily dispersible powdered form via Pulmatrix’s iSPERSE platform.

PUR1500 is still being assessed for formulation feasibility, which means that it may or may not progress to clinical-stage development.

How PUR1500 Works

PUR1500 may suppress the fibrotic pathway in the lungs’ interstitium. The interstitium is the tissue between the pulmonary alveoli and the bloodstream, where oxygen is transferred from the lungs to the blood.

Pulmatrix believes that by using its iSPERSE formulation technology, PUR1500 could be delivered in an effective therapeutic dose to suppress fibrosis, reduce systemic exposure of the drug, and lower side effects.

Pulmonary Fibrosis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

  1. http://pulmatrix.com/pipeline.html
  2. https://radiopaedia.org/articles/pulmonary-interstitium
  3. http://ir.pulmatrix.com/news-releases?item=21